Abstract
Patients with acute leukemias of undifferentiated lineage (AUL) generally have guarded prognosis. Here, we describe the first reported pediatric patient with AUL refractory to high-dose chemotherapy who achieved clinical remission with ALL maintenance therapy and 5-azacitidine. His induction remission was followed by consolidation with reduced toxicity haploidentical hematopoietic stem cell transplant (HSCT). At 9 months post-HSCT, the patient is alive and in remission. This combination therapy of remission induction with ALL maintenance therapy and 5-azacitidine and consolidation with reduced toxicity haploidentical HSCT is novel and promising for patients who lack conventional donors and are not candidates for myeloablative therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 1111-1112 |
Number of pages | 2 |
Journal | Pediatric Blood and Cancer |
Volume | 63 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2016 |
Keywords
- BMT
- Chemotherapy
- Leukemia
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology